CHIEF SCIENTIFIC OFFICER Qatanani Mo exercised 136,462 shares at a strike of $21.21 and sold $6,169,788 worth of shares (136,462 units at $45.21) (SEC Form 4)
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Scholar Rock Holding Corp [ SRRK ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 12/04/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 12/04/2025 | M | 65,625(1) | A | $26.05 | 174,589(2) | D | |||
| Common Stock | 12/04/2025 | M | 21,093(1) | A | $18.08 | 195,682(3) | D | |||
| Common Stock | 12/04/2025 | M | 5,607(1) | A | $4.86 | 201,289(4) | D | |||
| Common Stock | 12/04/2025 | M | 1,281(1) | A | $7.62 | 202,570(5) | D | |||
| Common Stock | 12/04/2025 | M | 11,250(1) | A | $10 | 213,820(6) | D | |||
| Common Stock | 12/04/2025 | M | 23,571(1) | A | $15.75 | 237,391(7) | D | |||
| Common Stock | 12/04/2025 | M | 8,035(1) | A | $35.15 | 245,426(8) | D | |||
| Common Stock | 12/04/2025 | S | 136,462(1) | D | $45.2125(9) | 108,964(10) | D | |||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $26.05 | 12/04/2025 | M(1) | 65,625 | (11) | 10/26/2031 | Common Stock | 65,625 | $0 | 4,375 | D | ||||
| Stock Option (Right to Buy) | $18.08 | 12/04/2025 | M(1) | 21,093 | (12) | 02/14/2032 | Common Stock | 21,093 | $0 | 1,407 | D | ||||
| Stock Option (Right to Buy) | $4.86 | 12/04/2025 | M(1) | 5,607 | (11) | 06/16/2032 | Common Stock | 5,607 | $0 | 0 | D | ||||
| Stock Option (Right to Buy) | $7.62 | 12/04/2025 | M(1) | 1,281 | (11) | 10/10/2032 | Common Stock | 1,281 | $0 | 1,282 | D | ||||
| Stock Option (Right to Buy) | $10 | 12/04/2025 | M(1) | 11,250 | (13) | 02/13/2033 | Common Stock | 11,250 | $0 | 14,063 | D | ||||
| Stock Option (Right to Buy) | $15.75 | 12/04/2025 | M(1) | 23,571 | (14) | 12/12/2034 | Common Stock | 23,571 | $0 | 53,036 | D | ||||
| Stock Option (Right to Buy) | $35.15 | 12/04/2025 | M(1) | 8,035 | (15) | 03/10/2035 | Common Stock | 8,035 | $0 | 34,820 | D | ||||
| Explanation of Responses: |
| 1. This transaction was effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2025. |
| 2. Consists of 65,625 shares of common stock and 108,964 RSUs. |
| 3. Consists of 86,718 shares of common stock and 108,964 RSUs. |
| 4. Consists of 92,325 shares of common stock and 108,964 RSUs |
| 5. Consists of 93,606 shares of common stock and 108,964 RSUs. |
| 6. Consists of 104,856 shares of common stock and 108,964 RSUs. |
| 7. Consists of 128,427 shares of common stock and 108,964 RSUs. |
| 8. Consists of 136,462 shares of common stock and 108,964 RSUs. |
| 9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.46, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 10. Consists of 108,964 RSUs. |
| 11. 1,282 shares remain unvested under this stock option. The first vesting event occurred on January 5, 2023 and the remainder vest in fifteen quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. |
| 12. 1,407 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2022 and the remainder vests in fifteen quarterly installments thereafter; provided the Reporting Person continues to have a service relationship with the Issuer on such vesting date. |
| 13. 14,063 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2023 and the remainder vests in fifteen quarterly installments thereafter; provided the Reporting Person continues to have a service relationship with the Issuer on such vesting date. |
| 14. 53,036 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2024 and the remainder vests in fifteen quarterly installments thereafter; provided the Reporting Person continues to have a service relationship with the Issuer on such vesting date. |
| 15. 34,820 shares remain unvested under this stock option. The first vesting event occurred on April 1, 2025 and the remainder vests in fifteen quarterly installments thereafter; provided the Reporting Person continues to have a service relationship with the Issuer on such vesting date. |
| /s/ Junlin Ho, Attorney-in-Fact for Mo Qatanani | 12/05/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||